Completed

PAVEA Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera (PAVE)

What is being collected

Data Collection

Collected from today forward - Prospective

Who is being recruted

Bone Marrow Diseases+6

+ Hematologic Diseases

+ Hemic and Lymphatic Diseases

From 18 to 120 Years

+2 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.

Observational

Study Start: August 2015

See protocol details

Summary

Principal SponsorNovartis Pharmaceuticals

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: August 17, 2015

Actual date on which the first participant was enrolled.

To achieve meaningful results in accordance with the study objective and to obtain long-term data from daily clinical practice in a real-world setting, the observation period under Jakavi® therapy is specified as 36 months.

Official TitleA Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera (PAVE)

NCT05853445

Principal SponsorNovartis Pharmaceuticals

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

467 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 120 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Bone Marrow DiseasesHematologic DiseasesHemic and Lymphatic DiseasesMyeloproliferative DisordersNeoplasmsNeoplasms by SitePolycythemia VeraBone Marrow NeoplasmsHematologic Neoplasms

Criteria

2 inclusion criteria required to participate

Adult male and female patients with PV for whom Jakavi® therapy is indicated according to the European summary of product characteristics

Patients who have been informed about this NIS and gave written consent

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 99 locations

Suspended

Novartis Investigative Site

Heidenheim, GermanyOpen Novartis Investigative Site in Google Maps

Suspended

Novartis Investigative Site

Iserlohn, Germany

Suspended

Novartis Investigative Site

Mannheim, Germany

Suspended

Novartis Investigative Site

Reutlingen, Germany

Completed99 Study Centers